Category: Market Share

Plasminogen is an inactive form of plasmin released by the liver in the systemic circulation, it is a serine protease and its objective is the dissolution of fibrin blood clots. Acquired and hereditary plasminogen deficiency increases the risk of thromboembolic disease. Thrombosis is dominating the application segment for the plasminogen market. Rising prevalence of pulmonary embolism in elderly patients and a significant increase in the inherited plasminogen deficiency of plasminogen together drive the market growth.  As per the recent research findings provided by the World Health Organization (WHO), the prevalence…

Read More

Type 1 hyperlipoproteinemia is also called familial lipoprotein lipase deficiency is an inherited genetic disorder, it is a rare disease with a global prevalence rate of 1 to 2 per 1,000,000 people. Currently the drugs used for its clinical treatment are Alipogene Tiparvovec, lomitapide mesylate, pradigastat sodium, etc. Hypertriglyceridemia is dominating the indication segment for the type 1 hyperlipoproteinemia drug market. It is manifested by the triglyceride blood serum level of above 500mg/dl. The excess levels of triglyceride and chylomicrons in the blood are due to a lack of familial…

Read More